维普期刊资源整合服务平台（V6.5）

36篇 您的检索式：作者名="Dienstmann"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer显示文摘	Leticia De Mattos-Arruda Rodrigo Dienstmann Josep Tabernero	2011	Clinical Colorectal Cancer2011，，4：	2
2	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated with Patient Outcomes显示文摘	Frank A. Sinicrope Qian Shi Thomas C. Smyrk Stephen N. Thibodeau Rodrigo Dienstmann Justin Guinney Brian M. Bot Sabine Tejpar Mauro Delorenzi Richard M. Goldberg Michelle Mahoney Daniel J. Sargent Steven R. Alberts	2014	Gastroenterology2014，，：	2
3	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal caner 显示文摘	Dienstmann R de Dosso S Felip E	2012	Mol Oncol2012，6，1：	1
4	Targeting the PI3K/Akt/mTOR pathway–beyond rapalogs显示文摘	Markman B Dienstmann R Tabernero J	2010	Oncotarget2010，1，7：	1
5	Targeting thePI3K/Akt/mT0R pathway-beyond rapalogs 显示文摘	Markman B Dienstmann R Tabernero J	2010	Oncotarget2010，1，：	1
6	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal caner显示文摘	Dienstmann R de Dosso S Felip E	2012	Mol Oncol2012，6，1：	1
7	The consensus molecular subtypes of colorectal cancer显示文摘	Guinney J Dienstmann R Wang X	2015	Nat Med2015，21，11：	1
8	Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs 显示文摘	Markman B Dienstmann R Tabemero J	2010	Oncotarget2010，1，7：	1
9	Personalizing therapy with tar- geted agents in non-small cell lung cancer 显示文摘	Dienstmann R Martinez P Felip E	2011	Oncotarget2011，2，3：	1
10	Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes显示文摘	Enrique Sanz-García Elena Elez Teresa Macarulla Rodrigo Dienstmann Ramon Salazar Josep Tabernero	2014	Current Colorectal Cancer Reports2014，，1：	1
11	Genomic aberra- tions in the FGFR pathway: opportunities for targeted therapies in solid tumors显示文摘	Dienstmann R Rodon J Prat A	2014	Ann Oncol2014，25，3：	1
12	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer显示文摘	Dienstmann R De Dosso S Felip E	2012	Mol Oncol2012，6，1：	1
13	The consensus molecular subtypes of eoloreetal cancer 显示文摘	Guinney J Dienstmann R Wang X	2015	Nat Med2015，21，11：	1
14	Picking the point of inhibition:a comparative review of PI3K/AKT/mTOR pathway inhibitors 显示文摘	DIENSTMANN R RODON J SERRA V	2014	Mol Cancer Ther2014，13，5：	1
15	Safety andPharmcieokinetics/tiarmacodynaniics of the First-in-ClassDual Action HER3/EGFR Antibody MEHD7945A in lo-cally Advanced or Metastatic Epithelial Tumors显示文摘	Juric D Dienstmann R Cervantes A	2015	ClinCancer Res2015，21，11：	1
16	Development ofPI3K inhibitors: lessons learned from early clinical trials显示文摘	Rodon J Dienstmann R Serra V	2013	Nat Rev Clin Oncol2013，10，3：	1
17	Development of molecular biomarkers in individualized treatment of colorectal canc- er显示文摘	De Mattos-Arruda L Dienstmann R Tabernero J	2011	Clin Colorectal Cancer2011，10，4：	1
18	Genomic aherrations in the FGFR pathway: opportunities for targeted therapies in solid tumors显示文摘	Dienstmann R RodonJ Prat A at al	2014	Ann Oncol2014，25，3：	1
19	Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs 显示文摘	DIENSTMANN R BRANA I RODON J	2011	Oncologist2011，16，12：	1
20	Drug deve- lopment to overcome resistance to EGFR inhibitors in lungand colorectal cancer 显示文摘	DIENSTMANN R DE DOSSO S] FELIP E	2012	Mol 0ncol2012，6，1：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示